1	Altered pre-existing SARS-CoV-2-specific T cell responses in elderly individuals
2	
3	Naoyuki Taira ¹ , Sakura Toguchi ¹ , Mio Miyagi ¹ , Tomoari Mori ² , Hiroaki Tomori ³ , Koichi
4	Oshiro ⁴ , Osamu Tamai ⁵ , Mitsuo Kina ⁶ , Masatake Miyagi ⁷ , Kentaro Tamaki ⁸ , Mary K
5	Collins ⁹ , and Hiroki Ishikawa ¹
6	
7	
8	¹ Immune Signal Unit, Okinawa Institute of Science and Technology, Graduate University
9	(OIST), Onna-son, Okinawa, Japan.
10	² Research Support Division, Occupational Health and Safety, OIST, Onna-son, Okinawa,
11	Japan
12	³ Yaesu Clinic, Naha-city, Okinawa, Japan
13	⁴ Ohama Daiichi Hospital, Naha-city, Okinawa, Japan
14	⁵ Akebono Clinic, Naha-city, Okinawa, Japan
15	⁶ Kina Clinic, Naha-city, Okinawa, Japan
16	⁷ Arakawa Clinic, Naha-city, Okinawa, Japan
17	⁸ Naha-Nishi Clinic, Department of Breast Surgery, Naha-city, Okinawa, Japan
18	⁹ Research Support Division, Office of the Provost, OIST, Onna-son, Okinawa, Japan.
19	
20	
21	Corresponding author
22	Hiroki Ishikawa PhD
23	hiroki.ishikawa@oist.jp
24	Tel: 81-098-966-1601
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	

37 Abstract

38 Pre-existing SARS-CoV-2-specific T cells, but not antibodies, have been detected in some 39 unexposed individuals. This may account for some of the diversity in clinical outcomes 40 ranging from asymptomatic infection to severe COVID-19. Although age is a risk factor for COVID-19, how age affects SARS-CoV-2-specific T cell responses remains unknown. 41 42 We found that some pre-existing T cell responses to specific SARS-CoV-2 proteins, Spike 43 (S) and Nucleoprotein (N), were significantly lower in elderly donors (>70 years old) who 44 were seronegative for S than in young donors. However, substantial pre-existing T cell 45 responses to the viral membrane (M) protein were detected in some elderly donors. These 46 responses likely compensate for loss of T cell responses specific to S and N. In contrast, 47 young and elderly donors exhibited comparable T cell responses to S, N, and M proteins after infection with SARS-CoV-2. M-specific responses were mediated by CD4 T cells 48 49 producing interferon- γ in both seronegative and seropositive individuals. T cells in 50 seronegative elderly donors responded to various M-derived peptides, while the response 51 after SARS-CoV-2 infection was apparently focused on a single peptide. These data suggest that diversity of target antigen repertoire for pre-existing SARS-CoV-2-specific 52 53 T cells declines with age, but the magnitude of pre-existing T cell responses is maintained 54 by T cells reactive to specific viral proteins such as M. A better understanding of the role of pre-existing SARS-CoV-2-specific T cells that are less susceptible to age-related loss 55

56 may contribute to development of more effective vaccines for elderly people.

57

58 Introduction

There is extensive individual variation in severity of coronavirus disease 2019 (COVID-59 19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), ranging 60 61 from asymptomatic infection to fatal pneumonia (1). Various factors, including age, sex, and comorbidities such as obesity and diabetes, influence the risk of severe COVID-19 62 (2-4). For example, morbidity and mortality among the elderly are significantly higher 63 64 than among the young (2). Consideration of protective measures for individuals vulnerable to COVID-19 should be particularly important to control the pandemic (5). 65 However, the cellular and molecular bases of the variable risk of COVID-19 remain 66 67 poorly understood.

T cells are assumed to mediate both protective and pathogenic immune responses to SARS-CoV-2 infection (6, 7). The magnitude and quality of T cell responses induced by SARS-CoV-2 infection are highly heterogeneous and are likely associated with COVID-19 clinical outcomes. For example, SARS-CoV-2-specific T cell numbers and their interferon- γ (IFN- γ) expression in severe COVID-19 patients are lower than in mild COVID-19 patients (8-10). Furthermore, asymptomatic COVID-19 patients tend to have

74	increased SARS-CoV-2-specific T cells expressing higher levels of IFN- γ compared to
75	symptomatic patients (11). This individual variation in T cell responses may be partly
76	explained by heterogeneity in levels of pre-existing SARS-CoV-2-reactive T cells.
77	Some individuals who have not been exposed to SARS-CoV-2 have nonetheless
78	acquired SARS-CoV-2-reactive T cells, probably through exposure to other common cold
79	coronaviruses (12-14). Pre-existing CD4 and CD8 memory T cells, specific to various
80	SARS-CoV-2 proteins, including the structural proteins, Spike (S), Membrane (M), and
81	Nucleoprotein (N), have been detected with significant individual variation (D. Wyllie et
82	al., manuscript posted on medRxiv DOI: 10.1101/2020.11.02.20222778). These pre-
83	existing SARS-CoV-2-reacive T cells are associated with immune protection against
84	COVID-19; however, in other cases, they may exacerbate COVID-19 severity (15, 16).
85	As many of the current vaccines express the SARS-CoV-2 S protein, only pre-existing S-
86	reactive T cells are activated by these vaccines (Refs. 17 and L. Loyal et al., manuscript
87	posted on medRxiv DOI: 10.1101/2021.04.01.21252379). Several studies have reported
88	age-related differences in SARS-CoV-2-specific T cell responses in COVID-19 patients
89	(Refs. 9 and C. A. Cohen et al., manuscript posted on medRxiv DOI:
90	10.1101/2021.02.02.21250988); however, the effect of age on pre-existing SARS-CoV-
91	2-reactive T cells remains unknown.

92	In this study, we compared frequencies of T cells reactive to SARS-CoV-2 S, N,
93	and M antigens between young and elderly donors. The relatively elderly Okinawan
94	population, and the moderate rate of SARS-CoV-2 infection in Okinawa, allowed us to
95	examine pre-existing SARS-CoV-2-specific T cells in a cohort of elderly (>70 years old)
96	individuals. We found that pre-existing T cell responses to S and N antigens are
97	significantly impaired in elderly donors compared to young donors, but a proportion of
98	elderly donors exhibit significant, high levels of M-reactive T cell responses. These data
99	provide new insights into age-related alteration of pre-existing SARS-CoV-2-specific T
100	cells.
101	
102	
103	
104	
105	
106	
107	
108	
109	

110 Methods

111 Subjects

The study design was approved by the Okinawa Institute of Science and Technology, 112 113 Graduate University (OIST) human subjects ethics committee (applications HSR-2020-024, HSR-2020-028). All donors provided informed written consent. Young (20 to 50 114 115 years of age, n=66) and elderly volunteers (over 70 years of age, n=52) were recruited in 116 Okinawa, Japan, between October, 2020 and April, 2021. 90 donors (48 young and 42 117 elderly) had no history of COVID-19, while 28 donors (18 young and 10 elderly) who 118 recovered from COVID-19 had positive COVID-19 PCR test results 1-3 months before 119 blood collection. Plasma from each donor was tested for SARS-CoV-2-specific antibodies using SARS-Cov-2 Antibody Detection Kits (KURABO RF-NC001, RF-NC002) or 120 121 Cellex qSARS-Cov-2 IgG/IgM Cassette Rapid Tests (Cellex 5513C). Four (3 young and 122 1 elderly) of 90 donors who had no history of COVID-19 and 26 (16 young and 10 123 elderly) of 28 donors who had recovered from COVID-19 were seropositive for SARS-124 CoV-2 S antigen. Based on antibody test results, donors were grouped into seronegative 125 young (n=45, 40 % male, 60% female; mean age 38 years, age rage 23-49 years), 126 seronegative elderly (n=41, 17 % male, 83% female; mean age 81 years, age rage 70-93 years), seropositive young (n=19, 63 % male, 37% female; mean age 41 years, age rage 127

20-50 years), and seropositive elderly (n=11, 45 % male, 55% female; mean age 78 years,
age rage 70-91 years).

130

131 Peripheral blood mononuclear cells (PBMCs) and plasma isolation.

132 Blood collected samples were in heparin-coated tubes (TERUMO; 133 VP-H100K). PBMCs and plasma were separated using Leucosep tupes pre-filled with 134 Ficoll-Paque Plus (Greiner; 163288). After adding 5 mL of blood and 3 mL of AIM-V 135 medium (Thermo; 12055091), Leucosep tubes were centrifuged at 1,000 g at room 136 temperature for 10 min. The white layer containing PBMCs was collected, washed with 137 10 mL AIM-V medium and centrifuged for 7 min at 600 g, followed by a second washing with centrifugation for 7 min at 400 g. PBMC pellets were resuspended in 500 µL CTL 138 139 test medium (Cellular Technology Limited (CTL); CTLT-010). Fresh PBMCs were used 140 for IFN-y ELISpot assays. PBMCs used for flow cytometry analysis and epitope mapping 141 analysis were stored with CTL-cryo ABC media (CTL; CTLC-ABC) in liquid nitrogen. 142

143 IFN-γ ELISpot assay

Peptide pools for SARS-CoV-2 S (JPT; PM-WCPV-S-1), N (Miltenyi;130-126-698), and
M (Miltenyi;130-126-702) proteins dissolved in DMSO (500 μg/mL for S) or water (50

146	$\mu g/mL$ for N and M) were used for cell stimulation. IFN- γ ELISpot assays were performed
147	using Human IFN-γ Single-Color Enzymatic ELISpot kits (CTL; hIFNgp-2M), according
148	to the manufacturer's instructions. Briefly, freshly isolated PBMCs (1-4 x 10^5 cells per
149	well) were stimulated with $1\mu g/mL$ peptide solutions for each SARS-CoV-2 protein for
150	18-20 h. For each sample analysis, negative controls (cells treated with equimolar
151	amounts of DMSO) and positive controls (cells treated with 50 ng/mL phorbol 12-
152	myristate 13-acetate (PMA) and 1 μ g/mL ionomycin) were included. After incubation,
153	plates were washed and developed with detection reagents included in the kits. Spots were
154	counted using a CTL ImmunoSpot S6 Analyzer. Antigen-specific spot counts were
155	determined by subtracting background spot counts in a negative control well from the
156	wells treated with peptide pools. If >30 spots/ 10^6 PBMCs in the negative control well or
157	<30 spots/10 ⁶ PBMCs in the positive control well were detected, sample data were
158	excluded from analysis.

159

Flow cytometry 160

Frozen PBMCs were thawed, washed with CTL wash supplement (CTL; CTL-W-010), 161 and rested in CTL test medium overnight. Then, cells were resuspended in RPMI1640 162 (Gibco) medium supplemented with 5% (v/v) human AB-serum (PAN-Biotech; P30-163

164	2901), seeded into 96-well, U-bottom culture plates (10^6 cells per well), and either left
165	unstimulated (cells treated with equimolar amounts of DMSO) or stimulated with $1\mu g/mL$
166	SARS-CoV-2 M peptide pool for 7 h in the presence of 1µg/mL anti-CD40 (5C3;
167	Biolegend; 334302) and 1 μ g/mL anti-CD28 antibodies (CD28.2; Biolegend; 302934).
168	Brefeldin A (1µg/mL) (Biolegend; 420601) was added for the last 2 h. After stimulation,
169	cells were incubated with anti-Fc receptor-blocking antibody (Biolegend; 422301) and
170	NIR-Zomibie (Biolegend; 423106) and stained with anti-CD3 (OKT3; Biolegend; 1:200),
171	anti-CD4 (clone PPA-T4; Biolegend; 1:200), anti-CD8 (SK1; Biolegend; 1:200), anti-
172	CD45RA (HI100; Biolegend; 1:100), and anti-CCR7 (G043H7; Biolegend; 1:100)
173	antibodies. For intracellular cytokine analysis, cells were subsequently fixed and
174	permeabilized using Foxp3 Staining Buffer Sets (eBioscience; 00-5253-00) and stained
175	with anti-IFN- γ (B27; BD; 1:100), anti-TNF- α (MAb11; Biolegend; 1:20) and anti-IL-2
176	(MQ1-17H12; Biolegend; 1:20) antibodies. Samples were analyzed on a Fortessa X-20
177	(BD), and data were analyzed with FlowJo software version 10.7.1 (FlowJo LLC).
178	

Matrix peptide pools of SARS-CoV-2 M 179

180 Matrix peptide pools included in Epitope Mapping Peptide Set SARS-CoV-2 (VME1) (JPT EMPS-WCPV-VME-1) were used to analyze M epitopes recognized by T cells. 181

182	PBMCs (0.5-1.5 x 10^5) were stimulated with 1 µg/mL of each M matrix peptide pool (15
183	pools of 6-8 peptides) for 18 h and subjected to IFN- γ ELISpot assays.
184	
185	Statistical analysis
186	Unpaired t tests or Mann-Whitney U tests were performed using GraphPad Prism 9.1.0
187	software. Statistical details are provided in figure legends.
188	
189	
190	
191	
192	
193	
194	
195	
196	
197	
198	
199	

201 **Results**

202 Age-related differences in SARS-CoV-2-specific T cell responses

203 To assess whether there are age-related differences in SARS-CoV-2-specific T cell 204 responses, we collected peripheral blood from young (20 to 50 years of age) and elderly (>70 years of age) donors in Okinawa between October 2020 and April 2021. These 205 206 included 18 young and 10 elderly donors who had recovered from mild COVID-19 1-3 207 months prior to blood collection. Antibody tests using freshly purified sera showed that 208 93% of donors with previously diagnosed COVID-19 and 4% of those without, were seropositive for SARS-CoV-2 Spike (S). Then we divided donors into 4 groups: young 209 210 seronegative (n=45), elderly seronegative (n=41), young seropositive (n=19), and elderly seropositive (n=11). 211

212	To compare SARS-CoV-2-specific T cell responses between age groups we
213	performed Interferon- γ (IFN- γ) ELISpot assays using freshly purified peripheral blood
214	mononuclear cells (PBMCs) stimulated with each of 4 peptide pools covering the major
215	viral structural proteins [N-terminal S (S1), C-terminal S (S2), Membrane (M), or
216	Nucleoprotein (N)]. First, we analyzed the sum of spots formed by IFN- γ -expressing cells
217	reactive to S1, S2, N, or M antigens (hereafter referred to as spots of SNM-reactive T

218	cells), indicating the magnitude of SARS-CoV-2-specific T cell responses in each donor.
219	Almost all seropositive donors exhibited strong T cell responses to SARS-CoV-2 antigens
220	regardless of age; the frequency of SNM-reactive spots was >40 per 10^6 PBMCs in 92%
221	of seropositive donors. The frequency of SNM-reactive T cells in seronegative donors
222	was more variable than in seropositive donors, but a substantial proportion of
223	seronegative donors exhibit T cell responses comparable to those of seropositive donors
224	(53% of young donors and 42% of elderly donors had >40 spots per 10^6 PBMCs). In both
225	seronegative and seropositive populations, there were no significant differences in the
226	frequency of SNM-reactive T cells between young (seronegative; median:53, IQR:21-96,
227	seropositive; meidan:312, IQR:75-1509) and elderly (seronegative; median:32, IQR:7-
228	331, seropositive; meidan:778, IQR:351-2392) (Fig. 1A, 1B).
229	Next, we compared frequencies of T cells reactive to individual viral antigens
230	between young and elderly donors. Among seronegative donors, the frequencies of S-2-
231	and N-reactive T cells were significantly lower in elderly than in young persons (Fig. 1B).
232	However, there were no significant differences in the frequencies of S-1- and M-reactive
233	T cells between seronegative young and elderly donors (Fig. 1B). Consistent with
234	previous reports (12), T cell responses to S-2 were higher than S-1 in the seronegative
235	population (Fig. 1B). Frequencies of T cells specific to S1, S2, N, and M were comparable

between seropositive young and elderly donors (Fig. 1B).

237	We also analyzed intraindividual immunodominance of each SARS-CoV-2
238	antigen in donors who had >40 spots per 10^6 PBMCs. Remarkably, M-specific responses
239	were dominant in 6/23 young and 12/14 elderly seronegative donors (Fig. 2A). In contrast,
240	T cell responses specific to S-1 and S-2 were more prominent than M in seropositive
241	donors (Fig. 2B). Taken together, these data suggest that although SARS-CoV-2 infection
242	can induce comparable T cell responses to various viral antigens in young and elderly
243	individuals, pre-existing memory T responses specific to SARS-CoV-2 S and N antigens
244	decrease in elderly people, while M-specific T cell responses are maintained.

245

246 **Phenotypes of M-reactive T cells**

Given that a proportion of seronegative donors exhibited M-specific responses comparable to those of seropositive donors, we compared phenotypes of M-reactive T cells by flow cytometry analysis. We analyzed 5 seronegative (1 young and 4 elderly) and 5 seropositive (2 young and 3 elderly) donors who had high responses to the M peptide pool (M responders). We stimulated PBMCs with the M peptide pool and stained cells with anti-CD4 or anti-CD8 antibodies, followed by intracellular cytokine staining with anti-IFN-γ antibody. Upon stimulation with the M peptide pool, CD4 T cells but not CD8

255

T cells significantly increased expression of IFN- γ in both seronegative and seropositive M responders and at comparable levels (Fig. 3A, 3B).

We next analyzed CD45RA and CCR7 expression to determine proportions of 256257 naïve and memory cells among M-reactive CD4 T cells. Although there was significant variation between individuals in proportions of M-reactive CD4 T cells exhibiting naïve 258 (CD45RA⁻ CCR7⁺), effector memory (CD45RA⁺ CCR7⁻), and central memory 259 260 (CD45RA⁺ CCR7⁺) phenotypes, all M responders had M-reactive memory T cells (Fig. 3C). There was no obvious difference in the proportion of naïve, effector memory, and 261 262 central memory CD4 T cells between seronegative and seropositive M responders (Fig. 263 3C).

264 We also analyzed frequencies of cells expressing IL-2 and TNF- α among M-265 reactive CD4 T cells. Although several donors showed increased IL-2 and TNF-a 266 expression upon stimulation with M in both seronegative and seropositive M responders, 267 in seropositive donors, only IL-2 reached statistical significance (Fig. 3D). Seronegative 268 and seropositive M-responders showed no detectable difference in IL-2 and TFN- α 269 expression in T cells stimulated with M (Fig. 3D). Expression of TNF-α and IL-2 in IFN-270 γ -expressing CD4 T cells was comparable between seronegative and seropositive M 271 responders (Fig. 3E). These data indicate that M-reactive T cell responses are mediated

272	by CD4 T cells expressing IFN- γ in both seronegative and seropositive M responders,
273	suggesting that pre-existing M-reactive T cells and SARS-CoV-2-induced memory M-
274	specific T cells might serve similar functions in SARS-CoV-2 infection.

276 Epitopes of SARS-CoV-2 M protein

277 To compare epitopes recognized by M-reactive T cells of seronegative and 278 seropositive donors, we stimulated PBMCs isolated from M responders with SARS-279 CoV-2 M matrix pools (15 pools of 6-8 peptides) where each of 56 M-derived peptides (15-mers) is allocated to 2 different pools. In seropositive M responders, stimulation 280 with pools 5 and 13 induced high levels of IFN- γ responses (Fig. 4A). These matrix 281 pools shared a single peptide, M145-160, suggesting that the M145-160, which was 282 previously identified as an immunodominant viral epitope in COVID-19 convalescent 283 284 patents (18), is the epitope recognized by T cells of seropositive M responders. In 285 contrast, in seronegative M responders, stimulation of PBMCs with many M matrix pools induced comparable IFN-y responses (Fig. 4B), suggesting that various M 286 epitopes are recognized by pre-existing T cells. 287

288

289

291 **Discussion**

292 Our data indicate that a fraction of elderly donors possess significantly high levels of pre-existing SARS-CoV-2 M-specific T cell responses, though the frequency of 293 pre-existing SARS-CoV-2 S- and N-specific T cells in this population is lower. Other 294 295 recent studies have also reported an age-related decline of S-specific pre-existing T cells 296 (Refs. and L. Loyal et al., manuscript posted on medRxiv DOI: 19 297 10.1101/2021.04.01.21252379). These data suggest that pre-existing T cells specific to 298 SARS-CoV-2 are heterogeneously affected by age in a target antigen-dependent manner. 299 There was no obvious difference in the sum of IFN- γ -expressing cells specific to S, N, 300 and M antigens, suggesting that abundant M-specific T cells can compensate for the loss 301 of S- and N-specific T cells, at least in the magnitude of T cell-mediated IFN-y production, 302 in elderly individuals. Taken together, these data suggest that the diversity of target 303 antigen repertoire for pre-existing T cells may decline with age, but the magnitude of preexisting T cell responses can be maintained with T cells specific to certain viral proteins 304 305 such as M.

306 As the frequency of pre-existing T cells specific to viral structural proteins S, N, 307 and M is associated with protection from SARS-CoV-2 infection (D. Wyllie et al.,

308	manuscript posted on medRxiv DOI: 10.1101/2020.11.02.20222778) , focused M
309	responses might be particularly important for protection of elderly individuals who have
310	lower responses to S and N. Flow cytometry analyses revealed that CD4 T cells mainly
311	mediate M-specific T cell responses, and their naïve/memory phenotypes and their
312	capacity to produce IFN- γ , IL-2, and TNF- α cytokines were comparable between
313	seronegative and seropositive groups. The phenotypic similarity suggests that pre-
314	existing M-reactive T cells may serve similar functions to SARS-CoV-2-induced M-
315	specific memory T cells. We speculate that pre-existing M-specific CD4 T cells play a
316	protective role in SARS-CoV-2 infection by promoting cellular immunity through IFN- γ
317	production and humoral immunity by providing T cell help to S- and N-specific B cells
318	via linked recognition.
319	However, we cannot exclude the possibility that pre-existing M-specific T cells
320	are harmful for some elderly individuals. Several studies suggest that pre-existing SARS-
321	CoV-2-specific T cells are detrimental in COVID-19 (8). In particular, the frequency of
322	M-specific T cells in COVID-19 patients is thought to be a risk factor, as it is correlated
323	with age and severity of disease (8), although how pre-existing M-specific T cells affect
324	magnitude, kinetics and functions of M-specific T cell responses in COVID-19 patients
325	remains unclear. Thus, both protective and pathogenic functions of pre-existing M-

326	specific T cells can be speculated. A longitudinal comparison of susceptibility and
327	symptom severity of COVID-19 between individuals with and without high pre-existing
328	M-specific T cell responses might provide insights into this issue.
329	Despite defects in pre-existing T cell responses to S and N, most elderly donors
330	who recovered from mild COVID-19 had abundant T cells specific to S and N antigens
331	at levels comparable to those of young donors, suggesting that elderly individuals can
332	induce T cell responses against S and N antigens upon SARS-CoV-2 infection. However,
333	our analysis is limited to only a few patients who had recovered from mild COVID-19.
334	Therefore, the relationship between age-related alteration of pre-existing T cells and T
335	cell responses during infection in patients with diverse clinical outcomes of COVID-19
336	should be investigated in a larger, statistically valid test population.
337	Whether diverse SARS-CoV-2-induced T cell clones can mediate long-lasting
338	memory responses should be addressed in future studies. It has recently been shown that
339	SARS-CoV-2-induced memory T cells persist at least 6 months after infection (20).
340	Interestingly, SARS-CoV-1 infection induces long-lasting (>11 years) CD8 memory T
341	cells specific to $M_{141-155}$ peptide (21). Our data show that the overlapping peptide (M_{145-}
342	160) is immunodominant in SARS-CoV-2 infection, which is consistent with a recent study
343	showing CD4 T cell responses to the $M_{145-160}$ peptide in convalescent COVID-19 patients

344	(18). The amino acid sequence of $M_{145-160}$ peptide from SARS-CoV-2 shows high
345	homology with SARS-CoV-1 and other coronaviruses (SARS-CoV-1: 81.3%, NL63:
346	33.0%, OC43: 47.0%, 229E: 22.7%, HKU1: 47.0%). This short M peptide is likely a
347	potent inducer of SARS-CoV-2 M-specific memory T cells. In contrast, pre-existing T
348	cells likely recognize various M peptides, possibly including M145-160, rather than
349	focusing on this single M peptide, as we observed in epitope mapping analysis.
350	What induces pre-existing M-specific T cells? Common cold coronaviruses may
351	induce pre-existing SARS-CoV-2-specific T cell (22, 23). Amino acid sequence
352	homology between SARS-CoV-2 and other common cold coronaviruses is relatively high
353	for M (NL63: 25.2%, OC43: 36.9%, 229E: 26.7%, HKU1: 32.4%), S1 (NL63: 11.0%,
354	OC43: 15.4%, 229E: 12.8%, HKU1: 15.2%), S2 (NL63: 27.3%, OC43: 36.9%, 229E:
355	28.0%, HKU1: 35.3%), and N (NL63: 22.3%, OC43: 26.5%, 229E: 16.2%, HKU1:
356	26.5%). These coronaviruses may induce polyclonal M-specific T cells. Age-related loss
357	of memory T cells specific to common cold coronavirus S protein (19) supports the
358	hypothesis that pre-existing M-focused T cell responses are induced by common cold
359	coronavirus infection in elderly people. Our data showing higher frequency of pre-
360	existing T cells specific to S-2 than S-1 are also consistent with the fact that S-2 shows
361	higher homology between SARS-CoV-2 and other coronaviruses. However, some young

362	donors, as well as elderly donors, had abundant pre-existing T cells specific to M, but not
363	to S and N, suggesting that focused T cell responses to M are not necessarily due to age-
364	related loss of pre-existing T cells specific for S and N antigens. Interestingly, a recent
365	study reported that T cells specific to commensal bacteria can cross-react with SARS-
366	CoV-2 S antigen (X. Lu et al., manuscript posted on medRxiv DOI:
367	10.1101/2021.03.23.436573). Similarly, there may be specific microbes that induce pre-
368	existing M-specific T cells.

It is worth considering the potential of novel COVID-19 vaccines to induce M-369 370 specific immunity. Current vaccine strategies are to induce S-specific antibody and T cell 371 responses (24, 25). Recent studies reported a correlation between the frequency of pre-372 existing S-specific T cells and vaccine-induced S-specific T cell responses (L. Loyal et al., manuscript posted on medRxiv DOI: 10.1101/2021.04.01.21252379), which suggests 373 374 a role of pre-existing S-specific T cells in cognate T cell help. However, elderly 375 individuals likely would not benefit fully from pre-existing S-specific T cells. To enhance 376 vaccine efficacy among the elderly, it might be reasonable to consider a strategy to induce not only S-specific, but also M-specific immunity, using vaccines based on inactivated 377 378 viruses or M-fused S antigens. Linked recognition of M-specific T helper cells by Sspecific B cells can promote S-specific antibody production by overcoming the defect of 379

cognate T cell help in elderly individuals. Further characterization of M-specific T cells
in young and elderly may provide new insights into vaccine-induced immunity that is less
affected by age.

383

384 Acknowledgements

We thank physicians and nurses at KIN oncology Clinic for excellent support to collect blood samples from donors. We also thank Steven Aird for editing manuscript. We are also grateful to OIST Graduate University for its generous funding of the Immune Signal Unit.

389 References

- Merad, M., and J. C. Martin. 2020. Pathological inflammation in patients
 with COVID-19: a key role for monocytes and macrophages. *Nature Reviews Immunology* 20: 355-362.
- 2. O'Driscoll, M., G. Ribeiro Dos Santos, L. Wang, D. A. T. Cummings, A. S.
- Azman, J. Paireau, A. Fontanet, S. Cauchemez, and H. Salje. 2021. Agespecific mortality and immunity patterns of SARS-CoV-2. *Nature* 590:
 140-145.
- 397 3. Takahashi, T., M. K. Ellingson, P. Wong, B. Israelow, C. Lucas, J. Klein, J.
- 398 Silva, T. Mao, J. E. Oh, M. Tokuyama, P. Lu, A. Venkataraman, A. Park, F.
- Liu, A. Meir, J. Sun, E. Y. Wang, A. Casanovas-Massana, A. L. Wyllie, C.
- 400 B. F. Vogels, R. Earnest, S. Lapidus, I. M. Ott, A. J. Moore, A. Shaw, J. B.
- 401 Fournier, C. D. Odio, S. Farhadian, C. Dela Cruz, N. D. Grubaugh, W. L.
- 402 Schulz, A. M. Ring, A. I. Ko, S. B. Omer, and A. Iwasaki. 2020. Sex
- differences in immune responses that underlie COVID-19 disease
 outcomes. *Nature* 588: 315-320.
- 405 4. Stefan, N., A. L. Birkenfeld, and M. B. Schulze. 2021. Global pandemics
 406 interconnected obesity, impaired metabolic health and COVID-19.

- 407 *Nature Reviews Endocrinology* 17: 135-149.
- 408 5. Krammer, F. 2020. SARS-CoV-2 vaccines in development. *Nature* 586:
 409 516-527.
- 410 6. Fajgenbaum, D. C., and C. H. June. 2020. Cytokine Storm. *New England*411 *Journal of Medicine* 383: 2255-2273.
- 412 7. De Candia, P., F. Prattichizzo, S. Garavelli, and G. Matarese. 2021. T Cells:
- 413 Warriors of SARS-CoV-2 Infection. *Trends in Immunology* 42: 18-30.
- 414 8. Sattler, A., S. Angermair, H. Stockmann, K. M. Heim, D. Khadzhynov, S.
- 415 Treskatsch, F. Halleck, M. E. Kreis, and K. Kotsch. 2020. SARS-CoV-2-
- 416 specific T cell responses and correlations with COVID-19 patient
- 417 predisposition. *Journal of Clinical Investigation* 130: 6477-6489.
- 418 9. Rydyznski Moderbacher, C., S. I. Ramirez, J. M. Dan, A. Grifoni, K. M.
- 419 Hastie, D. Weiskopf, S. Belanger, R. K. Abbott, C. Kim, J. Choi, Y. Kato, E.
- 420 G. Crotty, C. Kim, S. A. Rawlings, J. Mateus, L. P. V. Tse, A. Frazier, R.
- 421 Baric, B. Peters, J. Greenbaum, E. Ollmann Saphire, D. M. Smith, A. Sette,
- 422 and S. Crotty. 2020. Antigen-Specific Adaptive Immunity to SARS-CoV-2
- 423 in Acute COVID-19 and Associations with Age and Disease Severity. *Cell*
- 424 183: 996-1012.e1019.

425	10.	Chen, G., D. Wu, W. Guo, Y. Cao, D. Huang, H. Wang, T. Wang, X. Zhang,
426		H. Chen, H. Yu, X. Zhang, M. Zhang, S. Wu, J. Song, T. Chen, M. Han, S.
427		Li, X. Luo, J. Zhao, and Q. Ning. 2020. Clinical and immunological features
428		of severe and moderate coronavirus disease 2019. Journal of Clinical
429		Investigation 130: 2620-2629.
430	11.	Le Bert, N., H. E. Clapham, A. T. Tan, W. N. Chia, C. Y. L. Tham, J. M.
431		Lim, K. Kunasegaran, L. W. L. Tan, CA. Dutertre, N. Shankar, J. M. E.
432		Lim, L. J. Sun, M. Zahari, Z. M. Tun, V. Kumar, B. L. Lim, S. H. Lim, A.
433		Chia, YJ. Tan, P. A. Tambyah, S. Kalimuddin, D. Lye, J. G. H. Low, LF.
434		Wang, W. Y. Wan, L. Y. Hsu, A. Bertoletti, and C. C. Tam. 2021. Highly
435		functional virus-specific cellular immune response in asymptomatic SARS-
436		CoV-2 infection. Journal of Experimental Medicine 218.
437	12.	Braun, J., L. Loyal, M. Frentsch, D. Wendisch, P. Georg, F. Kurth, S.
438		Hippenstiel, M. Dingeldey, B. Kruse, F. Fauchere, E. Baysal, M. Mangold,
439		L. Henze, R. Lauster, M. A. Mall, K. Beyer, J. Rohmel, S. Voigt, J. Schmitz,
440		S. Miltenyi, I. Demuth, M. A. Muller, A. Hocke, M. Witzenrath, N. Suttorp,
441		F. Kern, U. Reimer, H. Wenschuh, C. Drosten, V. M. Corman, C.
442		Giesecke-Thiel, L. E. Sander, and A. Thiel. 2020. SARS-CoV-2-reactive T

443		cells in healthy donors and patients with COVID-19. Nature 587: 270-274.
444	13.	Le Bert, N., A. T. Tan, K. Kunasegaran, C. Y. L. Tham, M. Hafezi, A. Chia,
445		M. H. Y. Chng, M. Lin, N. Tan, M. Linster, W. N. Chia, M. I. C. Chen, L
446		F. Wang, E. E. Ooi, S. Kalimuddin, P. A. Tambyah, J. GH. Low, YJ. Tan,
447		and A. Bertoletti. 2020. SARS-CoV-2-specific T cell immunity in cases of
448		COVID-19 and SARS, and uninfected controls. <i>Nature</i> 584: 457-462.
449	14.	Woldemeskel, B. A., A. K. Kwaa, C. C. Garliss, O. Laeyendecker, S. C. Ray,
450		and J. N. Blankson. 2020. Healthy donor T cell responses to common cold
451		coronaviruses and SARS-CoV-2. Journal of Clinical Investigation 130:
452		6631-6638.
452 453	15.	6631-6638. Bacher, P., E. Rosati, D. Esser, G. R. Martini, C. Saggau, E. Schiminsky, J.
	15.	
453	15.	Bacher, P., E. Rosati, D. Esser, G. R. Martini, C. Saggau, E. Schiminsky, J.
453 454	15.	Bacher, P., E. Rosati, D. Esser, G. R. Martini, C. Saggau, E. Schiminsky, J. Dargvainiene, I. Schroder, I. Wieters, Y. Khodamoradi, F. Eberhardt, M.
453 454 455	15.	Bacher, P., E. Rosati, D. Esser, G. R. Martini, C. Saggau, E. Schiminsky, J. Dargvainiene, I. Schroder, I. Wieters, Y. Khodamoradi, F. Eberhardt, M. Vehreschild, H. Neb, M. Sonntagbauer, C. Conrad, F. Tran, P. Rosenstiel,
453 454 455 456	15.	Bacher, P., E. Rosati, D. Esser, G. R. Martini, C. Saggau, E. Schiminsky, J. Dargvainiene, I. Schroder, I. Wieters, Y. Khodamoradi, F. Eberhardt, M. Vehreschild, H. Neb, M. Sonntagbauer, C. Conrad, F. Tran, P. Rosenstiel, R. Markewitz, K. P. Wandinger, M. Augustin, J. Rybniker, M. Kochanek, F.
453 454 455 456 457	15.	 Bacher, P., E. Rosati, D. Esser, G. R. Martini, C. Saggau, E. Schiminsky, J. Dargvainiene, I. Schroder, I. Wieters, Y. Khodamoradi, F. Eberhardt, M. Vehreschild, H. Neb, M. Sonntagbauer, C. Conrad, F. Tran, P. Rosenstiel, R. Markewitz, K. P. Wandinger, M. Augustin, J. Rybniker, M. Kochanek, F. Leypoldt, O. A. Cornely, P. Koehler, A. Franke, and A. Scheffold. 2020.

461	16.	Chen, Z., and E. John Wherry. 2020. T cell responses in patients with
462		COVID-19. Nature Reviews Immunology 20: 529-536.
463	17.	Sahin, U., A. Muik, E. Derhovanessian, I. Vogler, L. M. Kranz, M. Vormehr,
464		A. Baum, K. Pascal, J. Quandt, D. Maurus, S. Brachtendorf, V. Lörks, J.
465		Sikorski, R. Hilker, D. Becker, AK. Eller, J. Grützner, C. Boesler, C.
466		Rosenbaum, MC. Kühnle, U. Luxemburger, A. Kemmer-Brück, D.
467		Langer, M. Bexon, S. Bolte, K. Karikó, T. Palanche, B. Fischer, A. Schultz,
468		PY. Shi, C. Fontes-Garfias, J. L. Perez, K. A. Swanson, J. Loschko, I. L.
469		Scully, M. Cutler, W. Kalina, C. A. Kyratsous, D. Cooper, P. R. Dormitzer,
470		K. U. Jansen, and Ö. Türeci. 2020. COVID-19 vaccine BNT162b1 elicits
471		human antibody and TH1 T cell responses. <i>Nature</i> 586: 594-599.
472	18.	Keller, M. D., K. M. Harris, M. A. Jensen-Wachspress, V. V. Kankate, H.
473		Lang, C. A. Lazarski, J. Durkee-Shock, PH. Lee, K. Chaudhry, K. Webber,
474		A. Datar, M. Terpilowski, E. K. Reynolds, E. M. Stevenson, S. Val, Z.
475		Shancer, N. Zhang, R. Ulrey, U. Ekanem, M. Stanojevic, A. Geiger, H.
476		Liang, F. Hoq, A. A. Abraham, P. J. Hanley, C. R. Cruz, K. Ferrer, L.
477		Dropulic, K. Gangler, P. D. Burbelo, R. B. Jones, J. I. Cohen, and C. M.
478		Bollard. 2020. SARS-CoV-2-specific T cells are rapidly expanded for

- therapeutic use and target conserved regions of the membrane protein. 479 Blood 136: 2905-2917. 480
- 19. Saletti, G., T. Gerlach, J. M. Jansen, A. Molle, H. Elbahesh, M. Ludlow, W. 481
- Li, B.-J. Bosch, A. D. M. E. Osterhaus, and G. F. Rimmelzwaan. 2020. 482
- Older adults lack SARS CoV-2 cross-reactive T lymphocytes directed to 483 human coronaviruses OC43 and NL63. Scientific Reports 10.

- Jiang, X.-L., G.-L. Wang, X.-N. Zhao, F.-H. Yan, L. Yao, Z.-Q. Kou, S.-X. 20. 485
- Ji, X.-L. Zhang, C.-B. Li, L.-J. Duan, Y. Li, Y.-W. Zhang, Q. Duan, T.-C. 486
- Wang, E.-T. Li, X. Wei, Q.-Y. Wang, X.-F. Wang, W.-Y. Sun, Y.-W. Gao, 487
- D.-M. Kang, J.-Y. Zhang, and M.-J. Ma. 2021. Lasting antibody and T cell 488
- responses to SARS-CoV-2 in COVID-19 patients three months after 489 infection. Nature Communications 12. 490
- Ng, O.-W., A. Chia, A. T. Tan, R. S. Jadi, H. N. Leong, A. Bertoletti, and 21. 491
- Y.-J. Tan. 2016. Memory T cell responses targeting the SARS coronavirus 492 persist up to 11 years post-infection. Vaccine 34: 2008-2014. 493
- 22. Sagar, M., K. Reifler, M. Rossi, N. S. Miller, P. Sinha, L. F. White, and J. P. 494
- Mizgerd. 2021. Recent endemic coronavirus infection is associated with 495
- less-severe COVID-19. Journal of Clinical Investigation 131. 496

497	23.	Mateus, J., A. Grifoni, A. Tarke, J. Sidney, S. I. Ramirez, J. M. Dan, Z. C.
498		Burger, S. A. Rawlings, D. M. Smith, E. Phillips, S. Mallal, M. Lammers, P.
499		Rubiro, L. Quiambao, A. Sutherland, E. D. Yu, R. Da Silva Antunes, J.
500		Greenbaum, A. Frazier, A. J. Markmann, L. Premkumar, A. De Silva, B.
501		Peters, S. Crotty, A. Sette, and D. Weiskopf. 2020. Selective and cross-
502		reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science 370:
503		89-94.
504	24.	Corbett, K. S., D. K. Edwards, S. R. Leist, O. M. Abiona, S. Boyoglu-
505		Barnum, R. A. Gillespie, S. Himansu, A. Schäfer, C. T. Ziwawo, A. T.
506		Dipiazza, K. H. Dinnon, S. M. Elbashir, C. A. Shaw, A. Woods, E. J. Fritch,
507		D. R. Martinez, K. W. Bock, M. Minai, B. M. Nagata, G. B. Hutchinson, K.
508		Wu, C. Henry, K. Bahl, D. Garcia-Dominguez, L. Ma, I. Renzi, WP. Kong,
509		S. D. Schmidt, L. Wang, Y. Zhang, E. Phung, L. A. Chang, R. J. Loomis, N.
510		E. Altaras, E. Narayanan, M. Metkar, V. Presnyak, C. Liu, M. K. Louder,
511		W. Shi, K. Leung, E. S. Yang, A. West, K. L. Gully, L. J. Stevens, N. Wang,
512		D. Wrapp, N. A. Doria-Rose, G. Stewart-Jones, H. Bennett, G. S. Alvarado,
513		M. C. Nason, T. J. Ruckwardt, J. S. McLellan, M. R. Denison, J. D. Chappell,
514		I. N. Moore, K. M. Morabito, J. R. Mascola, R. S. Baric, A. Carfi, and B. S.

515		Graham. 2020. SARS-CoV-2 mRNA vaccine design enabled by prototype
516		pathogen preparedness. Nature 586: 567-571.
517	25.	Polack, F. P., S. J. Thomas, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart,
518		J. L. Perez, G. Pérez Marc, E. D. Moreira, C. Zerbini, R. Bailey, K. A.
519		Swanson, S. Roychoudhury, K. Koury, P. Li, W. V. Kalina, D. Cooper, R.
520		W. Frenck, L. L. Hammitt, Ö. Türeci, H. Nell, A. Schaefer, S. Ünal, D. B.
521		Tresnan, S. Mather, P. R. Dormitzer, U. Şahin, K. U. Jansen, and W. C.
522		Gruber. 2020. Safety and Efficacy of the BNT162b2 mRNA Covid-19
523		Vaccine. New England Journal of Medicine 383: 2603-2615.

525 Figure Legends

526 Fig. 1. Altered pre-existing T cell responses to SARS-CoV-2 structural proteins in

- 527 elderly donors.
- PBMCs isolated from seronegative (**A**) and seropositive (**B**) young (20-50 years of age) and elderly (>70 years of age) donors were stimulated with peptide pools for SARS-CoV-2 S, N, and M proteins and subjected to IFN- γ ELISpot analysis. Spot-forming units representing the frequency of IFN- γ -secreting cells in seronegative young (n=45), seronegative elderly (n=41), seropositive young (n=19), and seropositive elderly (n=11) are shown. The sum of spots formed by cells stimulated with S, N, and M (SNM) is also shown. Statistical comparisons between age groups utilized the Mann-Whitney test.
- 535 *P<0.05, ns: not significant.

536

537	Fig. 2. N	A-specific p	ore-existing T	cell res	ponses pr	redominate i	n elderly	/ donors.

538 Ratios of spots formed by cells stimulated with SARS-CoV-2 S, N, and M peptide pools

- 539 in ELISpot data (in Fig. 1.) were analyzed in seronegative (A) and seropositive (B) donors
- 540 who had >40 spots/ 10^6 PBMCs in the sum of spots formed by cells stimulated with S, N,

541 and M.

Fig. 3. Pre-existing and SARS-CoV-2-induced M-specific T cells exhibit similar phenotypes.

545	PBMCs isolated from seronegative (n=5) and seropositive (n=5) M responders were
546	stimulated with an M peptide pool for 7 hours and analyzed by flow cytometry. The flow
547	cytometry gating strategy was shown in Supplemental Figure 1. (A) Dot plots represent
548	IFN- γ expression in CD4 and CD8 T cells of subject #31 (seronegative, >70 years of age).
549	(B) Percentages of IFN- γ -expressing cells among CD4 and CD8 T cells were analyzed.
550	(C) Percentages of naïve (Tn), central memory (Tcm), and effector memory (Tem) among
551	IFN- γ -expressing cells stimulated with M. (D, E) Percentages of TNF- α - and IL-2-
552	expressing cells among total CD4 T cells (D) and IFN- γ -expressing CD4 T cells (E)
553	stimulated with M. (B-E) Data shown as mean \pm SD. Each dot represents an individual
554	donor. Blue and orange dots indicate results of young and elderly donors, respectively.
555	Statistical analysis utilized unpaired two-tailed Student's t tests. *P<0.05, ns: not
556	significant.


557


558 Fig. 4. SARS-CoV-2 M epitopes recognized by T cells.


PBMCs isolated from M responders in seropositive (A) and seronegative (B) groups were
stimulated with SARS-CoV-2 M matrix pools (15 pools) for 16 h and subjected to IFN-γ


- 561 ELISpot analysis. Spot-forming units representing the frequency of IFN-γ-secreting cells.
- 562 Blue and orange bars indicate results of young and elderly donors, respectively.














IFN-γ SFU/10⁶ PBMCs